Tobira Therapeutics Inc (TBRA) is Initiated by Cantor Fitzgerald to Buy, Price Target at $27

Tobira Therapeutics Inc (TBRA) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $27. Cantor Fitzgerald advised their investors in a research report released on Jul 6, 2016.

Many Wall Street Analysts have commented on Tobira Therapeutics Inc. H.C. Wainwright Initiated Tobira Therapeutics Inc on Apr 11, 2016 to “Buy”, Price Target of the shares are set at $22.

Tobira Therapeutics Inc closed down -0.49 points or -3.80% at $12.4 with 57,546 shares getting traded on Tuesday. Post opening the session at $12.92, the shares hit an intraday low of $12.23 and an intraday high of $12.97 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.

Tobira Therapeutics Inc

Leave a Reply

Tobira Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Tobira Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.